When was SirnaMed Therapeutics founded?

SirnaMed Therapeutics was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is SirnaMed Therapeutics located?

SirnaMed Therapeutics is headquartered in Sewickley, United States.

Who is the current CEO of SirnaMed Therapeutics?

Phong Tran and Jing-Zhou Hou s of SirnaMed Therapeutics.

Is SirnaMed Therapeutics a funded company?

SirnaMed Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jul 10, 2024.

When was the latest funding round of SirnaMed Therapeutics?

SirnaMed Therapeutics' latest funding was a $***** Seed round on Jul 10, 2024, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.54B in funding in 2026 to date.

Where does SirnaMed Therapeutics rank among its competitors?

SirnaMed Therapeutics ranks 1042nd amongst 2608 active competitors, of which 881 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of SirnaMed Therapeutics?

SirnaMed Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

SirnaMed Therapeutics - 2026 Company Profile, Team, Funding & Competitors

SirnaMed Therapeutics is a seed company based in Sewickley (United States), founded in 2023. It operates as a Developer of gene therapies for cancer treatment. SirnaMed Therapeutics has raised $1.25M in funding. The company has 2608 active competitors, including 881 funded and 644 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Sana Biotechnology.

Company Details

Developer of gene therapies for cancer treatment. It offers small interfering RNA (siRNA) therapies designed to selectively silence genes that drive cancer development, progression, and treatment resistance. It has nanoparticles (NPs)-based tumor-targeting platform to treat chemoimmunotherapy resistant cancer.

Key Metrics

Founded Year

2023

Location

Sewickley, United States

Stage

Seed

Total Funding

$1.25M in 1 round

Latest Funding Round

Seed, Jul 10, 2024, $*****

Ranked

1042^nd among 2608 active competitors

Similar Companies

Alnylam & 110 more

View SirnaMed Therapeutics' full profile

SirnaMed Therapeutics has raised a total funding of $1.25M over 1 round.

Here is the list of recent funding rounds of SirnaMed Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 10, 2024	4166672	Seed	4762614	2850223	6920308	9374698

Access funding benchmarks and valuations. Sign up today!

View details of SirnaMed Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SirnaMed Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of SirnaMed Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
1042nd	SirnaMed Therapeutics 2023, Sewickley (United States), Seed	Developer of gene therapies for cancer treatment	$1.25M	-	36/100